Log in

NASDAQ:AQST - Aquestive Therapeutics Stock Price, Forecast & News

0.00 (0.00 %)
(As of 02/17/2020 04:15 AM ET)
Today's Range
Now: $4.38
50-Day Range
MA: $4.76
52-Week Range
Now: $4.38
Volume421,782 shs
Average Volume654,459 shs
Market Capitalization$109.68 million
P/E RatioN/A
Dividend YieldN/A
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AQST



Sales & Book Value

Annual Sales$67.43 million
Book Value$0.40 per share


Net Income$-61,380,000.00
Net Margins-127.43%


Market Cap$109.68 million
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable

Receive AQST News and Ratings via Email

Sign-up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.

Aquestive Therapeutics (NASDAQ:AQST) Frequently Asked Questions

What is Aquestive Therapeutics' stock symbol?

Aquestive Therapeutics trades on the NASDAQ under the ticker symbol "AQST."

How were Aquestive Therapeutics' earnings last quarter?

Aquestive Therapeutics Inc (NASDAQ:AQST) announced its earnings results on Tuesday, August, 6th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.67) by $0.15. The business had revenue of $11.13 million for the quarter, compared to analysts' expectations of $10.46 million. Aquestive Therapeutics had a negative return on equity of 8,669.94% and a negative net margin of 127.43%. View Aquestive Therapeutics' Earnings History.

When is Aquestive Therapeutics' next earnings date?

Aquestive Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Aquestive Therapeutics.

What guidance has Aquestive Therapeutics issued on next quarter's earnings?

Aquestive Therapeutics updated its FY 2020 Pre-Market earnings guidance on Friday, January, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $35-45 million, compared to the consensus revenue estimate of $56.85 million.

What price target have analysts set for AQST?

4 Wall Street analysts have issued 1 year price objectives for Aquestive Therapeutics' stock. Their forecasts range from $10.00 to $36.00. On average, they expect Aquestive Therapeutics' share price to reach $19.25 in the next twelve months. This suggests a possible upside of 339.5% from the stock's current price. View Analyst Price Targets for Aquestive Therapeutics.

What is the consensus analysts' recommendation for Aquestive Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aquestive Therapeutics.

What are Wall Street analysts saying about Aquestive Therapeutics stock?

Here are some recent quotes from research analysts about Aquestive Therapeutics stock:
  • 1. According to Zacks Investment Research, "Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based in NJ, United States. " (1/15/2020)
  • 2. HC Wainwright analysts commented, "We utilize a discounted cash flow (DCF)-based assessment to value Aquestive Therapeutics shares. Using a composite of contributions from Sympazan and Libervant sales along with APL-130277 royalties, plus the impact of legacy revenues from royalties on sales of Suboxone and Zuplenz, we derive a total risk-adjusted net present value (rNPV) of $312M. We employ a discount rate of 15% and effective tax rate of 30%. Our probability of approval for Libervant is 90%, while we utilize a 75% probability of approval for APL-130277." (4/22/2019)

Has Aquestive Therapeutics been receiving favorable news coverage?

Press coverage about AQST stock has been trending somewhat positive on Monday, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aquestive Therapeutics earned a news impact score of 1.8 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Aquestive Therapeutics.

Who are some of Aquestive Therapeutics' key competitors?

What other stocks do shareholders of Aquestive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include AbbVie (ABBV), Aimmune Therapeutics (AIMT), Inovio Pharmaceuticals (INO), Micron Technology (MU), Alibaba Group (BABA), Roku (ROKU), Synergy Pharmaceuticals (SGYP), Anavex Life Sciences (AVXL), Opko Health (OPK) and Rigel Pharmaceuticals (RIGL).

Who are Aquestive Therapeutics' key executives?

Aquestive Therapeutics' management team includes the folowing people:
  • Mr. Keith J. Kendall, CEO, Pres & Director (Age 61)
  • Mr. John T. Maxwell, Sr. VP & CFO (Age 54)
  • Mr. Alexander Mark Schobel, Chief Innovation & Technology Officer (Age 60)
  • Mr. Daniel Barber, Sr. VP and Chief Strategy & Devel. Officer (Age 43)
  • Mr. Peter E. Boyd, Sr. VP of Operations & Value Delivery (Age 54)

When did Aquestive Therapeutics IPO?

(AQST) raised $60 million in an initial public offering on Wednesday, July 25th 2018. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

Who are Aquestive Therapeutics' major shareholders?

Aquestive Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (8.98%), Wildcat Capital Management LLC (1.82%), Oxford Asset Management LLP (1.24%), Granite Point Capital Management L.P. (0.64%), Laurion Capital Management LP (0.42%) and Renaissance Technologies LLC (0.32%). Company insiders that own Aquestive Therapeutics stock include Alexander Mark Schobel, Daniel Barber, Douglas K Bratton, James S Scibetta, John T Maxwell, Keith J Kendall, Peter E Boyd and Theresa Wood. View Institutional Ownership Trends for Aquestive Therapeutics.

Which institutional investors are selling Aquestive Therapeutics stock?

AQST stock was sold by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Wedbush Securities Inc. and Tower Research Capital LLC TRC . View Insider Buying and Selling for Aquestive Therapeutics.

Which institutional investors are buying Aquestive Therapeutics stock?

AQST stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Wildcat Capital Management LLC, Oxford Asset Management LLP, Granite Point Capital Management L.P., Laurion Capital Management LP, Renaissance Technologies LLC, Spark Investment Management LLC and Goldman Sachs Group Inc.. Company insiders that have bought Aquestive Therapeutics stock in the last two years include Alexander Mark Schobel, Daniel Barber, Douglas K Bratton, James S Scibetta, John T Maxwell, Keith J Kendall, Peter E Boyd and Theresa Wood. View Insider Buying and Selling for Aquestive Therapeutics.

How do I buy shares of Aquestive Therapeutics?

Shares of AQST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aquestive Therapeutics' stock price today?

One share of AQST stock can currently be purchased for approximately $4.38.

How big of a company is Aquestive Therapeutics?

Aquestive Therapeutics has a market capitalization of $109.68 million and generates $67.43 million in revenue each year. The company earns $-61,380,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis. Aquestive Therapeutics employs 277 workers across the globe.View Additional Information About Aquestive Therapeutics.

MarketBeat Community Rating for Aquestive Therapeutics (NASDAQ AQST)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  122 (Vote Outperform)
Underperform Votes:  141 (Vote Underperform)
Total Votes:  263
MarketBeat's community ratings are surveys of what our community members think about Aquestive Therapeutics and other stocks. Vote "Outperform" if you believe AQST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AQST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel